Literature DB >> 2365200

Orthotopic liver transplantation for graft-versus-host disease following bone marrow transplantation.

D F Rhodes1, W M Lee, J R Wingard, M D Pavy, G W Santos, B W Shaw, R P Wood, M F Sorrell, R S Markin.   

Abstract

Chronic graft-vs.-host disease occurs in 30%-50% of long-term survivors of allogeneic bone marrow grafts, and may eventuate in cirrhosis. In this study, a young woman, originally diagnosed as having acute myelogenous leukemia, underwent successful bone marrow transplantation but later developed graft-vs.-host disease-induced cirrhosis and recurrent variceal hemorrhage. She underwent successful orthotopic liver transplant. Her postoperative course was uncomplicated, with no evidence of rejection or recurrence of graft-vs.-host disease. As bone marrow transplantation is more widely used and survival improves, the number of patients with graft-vs.-host disease or venoocclusive disease resulting in cirrhosis is likely to increase. Hepatic transplantation should be considered for bone marrow transplant patients who develop end-stage liver disease.

Entities:  

Mesh:

Year:  1990        PMID: 2365200     DOI: 10.1016/0016-5085(90)91039-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  2 in total

Review 1.  Successful treatment of severe refractory hepatic graft-versus-host disease by cadaveric liver transplant.

Authors:  Amer M Zeidan; Jocelyn L Wozney; Michael Torbenson; Karen Krok; Javier Bolaños-Meade
Journal:  Leuk Lymphoma       Date:  2013-04-30

2.  Case Report: Liver as a Source of Hematopoietic Stem Cells After Liver Transplantation Following Hematopoietic Stem Cell Transplantation.

Authors:  Tomasz Jarmoliński; Monika Rosa; Blanka Rybka; Renata Ryczan-Krawczyk; Kornelia Gajek; Katarzyna Bogunia-Kubik; Maja Klaudel-Dreszler; Piotr Czubkowski; Piotr Kaliciński; Joanna Teisseyre; Marek Stefanowicz; Ewa Gorczyńska; Krzysztof Kałwak; Marek Ussowicz
Journal:  Front Pediatr       Date:  2022-03-23       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.